CN113227096A - 1,2,3-三氮唑并[1,5-a]吡嗪类衍生物的晶型及其制备方法 - Google Patents
1,2,3-三氮唑并[1,5-a]吡嗪类衍生物的晶型及其制备方法 Download PDFInfo
- Publication number
- CN113227096A CN113227096A CN202080007547.8A CN202080007547A CN113227096A CN 113227096 A CN113227096 A CN 113227096A CN 202080007547 A CN202080007547 A CN 202080007547A CN 113227096 A CN113227096 A CN 113227096A
- Authority
- CN
- China
- Prior art keywords
- compound
- ray powder
- powder diffraction
- triazole
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
本公开提供了1,2,3‑三氮唑并[1,5‑a]吡嗪类衍生物的晶型及其制备方法。具体而言,本公开提供了化合物(S)‑N5‑(3,4‑二氟苯基)‑6‑甲基‑N3‑((R)‑1,1,1‑三氟丙‑2‑基)‑6,7‑二氢‑[1,2,3]三氮唑并[1,5‑a]吡嗪‑3,5(4H)‑二甲酰胺的晶型及其制备方法。制备得到的晶型具有良好的稳定性以及临床应用价值。
Description
PCT国内申请,说明书已公开。
Claims (10)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2019100720486 | 2019-01-25 | ||
CN201910072048 | 2019-01-25 | ||
PCT/CN2020/073802 WO2020151746A1 (zh) | 2019-01-25 | 2020-01-22 | 1,2,3-三氮唑并[1,5-a]吡嗪类衍生物的晶型及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113227096A true CN113227096A (zh) | 2021-08-06 |
CN113227096B CN113227096B (zh) | 2022-04-12 |
Family
ID=71735561
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202080007547.8A Active CN113227096B (zh) | 2019-01-25 | 2020-01-22 | 1,2,3-三氮唑并[1,5-a]吡嗪类衍生物的晶型及其制备方法 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220081446A1 (zh) |
EP (1) | EP3915993A1 (zh) |
JP (1) | JP2022523035A (zh) |
KR (1) | KR20210120036A (zh) |
CN (1) | CN113227096B (zh) |
AU (1) | AU2020210998A1 (zh) |
BR (1) | BR112021014327A2 (zh) |
CA (1) | CA3126175A1 (zh) |
MX (1) | MX2021008929A (zh) |
TW (1) | TW202043233A (zh) |
WO (1) | WO2020151746A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202245772A (zh) * | 2021-02-04 | 2022-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種衣殼蛋白抑制劑的醫藥組成物及其製備方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016113273A1 (en) * | 2015-01-16 | 2016-07-21 | F. Hoffmann-La Roche Ag | Pyrazine compounds for the treatment of infectious diseases |
CN108727347A (zh) * | 2017-04-14 | 2018-11-02 | 江苏恒瑞医药股份有限公司 | 一种阿片样物质受体(mor)激动剂的晶型及其制备方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101686989B (zh) * | 2007-06-21 | 2016-10-19 | 卡拉治疗学股份有限公司 | 取代的咪唑并杂环 |
CN102875270B (zh) | 2012-09-24 | 2014-12-03 | 巨化集团公司 | 一种三氟甲基代胺的合成方法 |
UY35834A (es) * | 2013-11-14 | 2015-05-29 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Piperazinas de pirazolo sustituido como inhibidores de caseína quinasa 1 delta y epsilon |
CA3070004A1 (en) * | 2017-07-27 | 2019-01-31 | Jiangsu Hengrui Medicine Co., Ltd. | Piperazine heteroaryl derivative, preparation method therefor and use of same in medicine |
-
2020
- 2020-01-22 WO PCT/CN2020/073802 patent/WO2020151746A1/zh unknown
- 2020-01-22 JP JP2021542521A patent/JP2022523035A/ja active Pending
- 2020-01-22 TW TW109102337A patent/TW202043233A/zh unknown
- 2020-01-22 CA CA3126175A patent/CA3126175A1/en active Pending
- 2020-01-22 EP EP20745058.6A patent/EP3915993A1/en not_active Withdrawn
- 2020-01-22 CN CN202080007547.8A patent/CN113227096B/zh active Active
- 2020-01-22 BR BR112021014327-0A patent/BR112021014327A2/pt not_active Application Discontinuation
- 2020-01-22 KR KR1020217026840A patent/KR20210120036A/ko unknown
- 2020-01-22 US US17/425,495 patent/US20220081446A1/en active Pending
- 2020-01-22 MX MX2021008929A patent/MX2021008929A/es unknown
- 2020-01-22 AU AU2020210998A patent/AU2020210998A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016113273A1 (en) * | 2015-01-16 | 2016-07-21 | F. Hoffmann-La Roche Ag | Pyrazine compounds for the treatment of infectious diseases |
CN108727347A (zh) * | 2017-04-14 | 2018-11-02 | 江苏恒瑞医药股份有限公司 | 一种阿片样物质受体(mor)激动剂的晶型及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN113227096B (zh) | 2022-04-12 |
US20220081446A1 (en) | 2022-03-17 |
CA3126175A1 (en) | 2020-07-30 |
KR20210120036A (ko) | 2021-10-06 |
WO2020151746A1 (zh) | 2020-07-30 |
MX2021008929A (es) | 2021-08-24 |
AU2020210998A1 (en) | 2021-09-16 |
TW202043233A (zh) | 2020-12-01 |
JP2022523035A (ja) | 2022-04-21 |
BR112021014327A2 (pt) | 2021-09-28 |
EP3915993A1 (en) | 2021-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10017513B2 (en) | Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido [5,4-D][2]benzazepin-2-YL]amino}-2-methoxybenzoate | |
CN110577536B (zh) | 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用 | |
RU2633694C2 (ru) | Дейтерированный фениламинопиримидин и фармацевтическая композиция, содержащая такое соединение | |
PL172789B1 (pl) | Sposób wytwarzania nowych makrolidów imidazolilowych PL PL PL | |
US20210387989A1 (en) | Pyrrolo[2,3-d]pyrimidine tosylate salt, crystalline form thereof and manufacturing process and intermediates thereto | |
US20090076272A1 (en) | Polymorphs of eszopiclone malate | |
EP0918777A1 (en) | SELECTED DERIVATIVES OF K-252a | |
CN113227096B (zh) | 1,2,3-三氮唑并[1,5-a]吡嗪类衍生物的晶型及其制备方法 | |
KR20200092946A (ko) | 결정질 리나글립틴 중간체 및 리나글립틴 제조 공정 | |
US11230559B2 (en) | Solid forms of [(1 S)-1 -[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-D]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-Yl]proptl] acetate | |
KR20230002706A (ko) | 결정질 ret 억제제 | |
CN111484498B (zh) | 咪唑并[1,5-a]吡嗪类化合物的晶型及其制备方法 | |
CN111484497B (zh) | 咪唑并[1,5-a]吡嗪类衍生物的可药用盐、晶型及其制备方法 | |
US20220119415A1 (en) | Solid forms of [(1s)-1-[(2s,4r,5r)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate | |
CN112830919B (zh) | 苯并哌啶衍生物可药用盐及其制备方法 | |
RU2793918C2 (ru) | Ингибитор некроза клеток, способ его получения и применения | |
CN114728973B (zh) | 一种核蛋白抑制剂的晶型及其应用 | |
US20090082386A1 (en) | Ascomycin and pimecrolimus having reduced levels of desmethylascomycin and 32-deoxy-32-epichloro-desmethylascomycin respectively, and methods for preparation thereof | |
CN111718340A (zh) | 氘代Palbociclib化合物的晶型、制备方法及应用 | |
CN109824606A (zh) | 一种瑞舒伐他汀钙杂质以及瑞舒伐他汀钙质量控制方法 | |
EP2109613A2 (en) | Polymorphs of eszopiclone malate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40060005 Country of ref document: HK |